![]() |
New to the Huntington's Disease Lighthouse? |
||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home \ Treatment & Care \ Treatment \ Drugs \ Statins \ Related \ Updates
|
||||||||||||||
|
HD Lighthouse Editors Comment: There
is now support that HD onset and progression are immune related. Of interest
are three conditions directly addressed by this reference, Alzheimer's,
MS and Huntington's. Substantial evidence has been found that statins treat
Alzheimer's and MS.
Statins do more than lower cholesterol. Statins have immune related properties and they reduce the pro-oxidant effects of co-enzyme Q10. Statins may be the drug of choice to treat HD. Bring on the HD mice. --Jerry Posted to HDLighthouse: 20-Apl-2002
Lipitor (atorvastatin), the most frequently used cholesterol lowering agent in the world, also has the ability to influence the immune system and proved effective in reversing paralysis in a mouse model of multiple sclerosis. Dr. Sawsan Youssef, a postdoctoral fellow in the laboratory of Dr. Lawrence Steinman, Stanford University, reported the study on April 23 at the Experimental Biology 2002 meeting in New Orleans. Multiple sclerosis is caused by the immune system attacking the bodys own central nervous system, breaking down the myelin that sheathes and protects CNS nerves, impairing the bodys ability to move normally, and eventually causing paralysis. The T lymphocytes of the mice with which the research team worked are sensitized to brain antigens so that they produce an over-abundance of cytokines, pro-inflammatory chemicals that inflame the CNS, causing demylination of nerve sheaths through the same mechanism and in the same manner as happens in human multiple sclerosis. As in humans with MS, this mouse condition (called experimental autoimmune encephalomyelitis or EAE) can occur in either an acute or relapsing form. The researchers found that oral treatment with lipitor could prevent both the acute and relapsing form of the multiple sclerosis-like disease in the mice, and could also reverse symptoms in mice with the ongoing chronic relapsing form of the disease. Compared with control mice, the mice treated with lipitor had much less CNS inflammation. A close comparison of the lymphocytes of lipitor-treated and control-treated mice showed that lipitor prevented the induction of the pro-inflammatory cytokines and induced secretion of anti-inflammatory cytokines. Dr. Youssef and Dr. Steinman are working closely on this study with Dr. Scott Zamvil, University of California at San Francisco. Other members of the research team for this paper are Dr. Pedro Ruiz, Stanford, and Dr. Olaf Stuve, UCLA. ### |
|
|||||||||||||
| Disclaimer & Privacy
Policy | |
|